“Full-plastic jacket” with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413)

•FPJ treatment might be feasible in a population with a high clinical and angiographic risk profile.•A high adherence to the BRS specific implantation protocol remains crucial.•The treatment of CTO by FPJ might be a predictor of adverse outcome.